IREN (IREN) has been added to the Russell 1000 Index as the Russell U.S. Indexes shift from an annual to a semi-annual ...
Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today ...
NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...
15don MSN
This Talen Energy analyst begins coverage on a bullish note; here are top 5 initiations for Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.
View Relmada Therapeutics Inc RLMD stock quote prices, financial information, real-time forecasts, and company news from CNN.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus today and set a price target of $15.00. Introducing TipRanks MCP for Agents. Deliver institutional-grade market ...
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results